Literature DB >> 8227762

The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders.

W Greil1, W Ludwig-Mayerhofer, B Steller, A Czernik, H Giedke, B Müller-Oerlinghausen, M Osterheider, G A Rudolf, H Sauer, J Tegeler.   

Abstract

The paper reports on the process of patient recruitment for a controlled clinical multicenter study on the treatment of affective disorders. Two thirds of the patients screened did not participate because prophylactic treatment was either unnecessary or not justified for medical reasons. Further, a number of patients equal to that eventually allocated to the trial refused to participate for personal, idiosyncratic reasons. In spite of this, the patients in the trial were very similar to those not participating with respect to relevant variables such as age, sex, number of and intervals between previous episodes or severity of the present episode.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227762     DOI: 10.1016/0165-0327(93)90061-n

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

1.  Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network.

Authors:  Deborah A Zarin; Julia L Young; Joyce C West
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-01       Impact factor: 4.328

Review 2.  Lithium versus antidepressants in the long-term treatment of unipolar affective disorder.

Authors:  A Cipriani; K Smith; S Burgess; S Carney; G Goodwin; J Geddes
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

3.  Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study.

Authors:  W Greil; W Ludwig-Mayerhofer; N Erazo; R R Engel; A Czernik; H Giedke; B Müller-Oerlinghausen; M Osterheider; G A Rudolf; H Sauer; J Tegeler; T Wetterling
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.